US Patent Issued to Northwestern University on Sept. 15 for "Use of nucleotide synthesis inhibitors for targeted therapy in MLL3/4 compass mutant cancer" (Illinois Inventors)

ALEXANDRIA, Va., Sept. 15 -- United States Patent no. 12,734,173, issued on Sept. 15, was assigned to Northwestern University (Evanston, Ill.).

"Use of nucleotide synthesis inhibitors for targeted therapy in MLL3/4 compass mutant cancer" was invented by Ali Shilatifard (Chicago) and Zibo Zhao (Chicago).

According to the abstract* released by the U.S. Patent & Trademark Office: "Disclosed herein are methods and compositions for treating a subject comprising the administration of an effective amount of a nucleotide synthesis inhibitor to a subject in need of treatment for a MLL3/4 COMPASS deficient cancer or a MLL3/4 loss of function mutation."

The patent was filed on June 2, 2023, under Application No. 18/328,011.

*For further informatio...